IL287979A - Dosage regimens for administration of lag-3/pd-l1 bispecific antibody - Google Patents

Dosage regimens for administration of lag-3/pd-l1 bispecific antibody

Info

Publication number
IL287979A
IL287979A IL287979A IL28797921A IL287979A IL 287979 A IL287979 A IL 287979A IL 287979 A IL287979 A IL 287979A IL 28797921 A IL28797921 A IL 28797921A IL 287979 A IL287979 A IL 287979A
Authority
IL
Israel
Prior art keywords
lag
administration
bispecific antibody
dosage regimes
regimes
Prior art date
Application number
IL287979A
Other languages
English (en)
Hebrew (he)
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906807.1A external-priority patent/GB201906807D0/en
Priority claimed from GB201914040A external-priority patent/GB201914040D0/en
Priority claimed from GBGB2000318.2A external-priority patent/GB202000318D0/en
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of IL287979A publication Critical patent/IL287979A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL287979A 2019-05-14 2021-11-10 Dosage regimens for administration of lag-3/pd-l1 bispecific antibody IL287979A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906807.1A GB201906807D0 (en) 2019-05-14 2019-05-14 Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
GB201914040A GB201914040D0 (en) 2019-09-30 2019-09-30 Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GBGB2000318.2A GB202000318D0 (en) 2020-01-09 2020-01-09 Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
PCT/EP2020/063529 WO2020229626A1 (en) 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Publications (1)

Publication Number Publication Date
IL287979A true IL287979A (en) 2022-01-01

Family

ID=70775359

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287979A IL287979A (en) 2019-05-14 2021-11-10 Dosage regimens for administration of lag-3/pd-l1 bispecific antibody

Country Status (12)

Country Link
US (1) US20220275092A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969477A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022533578A (cg-RX-API-DMAC7.html)
KR (1) KR20220008316A (cg-RX-API-DMAC7.html)
CN (1) CN114206939A (cg-RX-API-DMAC7.html)
AU (1) AU2020275209A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022831A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139003A1 (cg-RX-API-DMAC7.html)
IL (1) IL287979A (cg-RX-API-DMAC7.html)
MX (1) MX2021013943A (cg-RX-API-DMAC7.html)
SG (1) SG11202112136RA (cg-RX-API-DMAC7.html)
WO (1) WO2020229626A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
CN118165116A (zh) * 2021-03-31 2024-06-11 美勒斯公司 新型多特异性抗体
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof
GB202304278D0 (en) 2023-03-23 2023-05-10 F Star Therapeutics Ltd Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7085709B2 (ja) 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗lag−3抗体、pd−1経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors

Also Published As

Publication number Publication date
SG11202112136RA (en) 2021-11-29
WO2020229626A1 (en) 2020-11-19
US20220275092A1 (en) 2022-09-01
JP2022533578A (ja) 2022-07-25
EP3969477A1 (en) 2022-03-23
KR20220008316A (ko) 2022-01-20
BR112021022831A2 (pt) 2022-01-18
CN114206939A (zh) 2022-03-18
CA3139003A1 (en) 2020-11-19
AU2020275209A1 (en) 2021-12-23
MX2021013943A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
LT4067387T (lt) Anti-pd-1-anti-vegfa bispecifinis antikūnas, farmacinė kompozicija ir jos panaudojimas
EP4003327A4 (en) Dosing regimens for oral complement factor d inhibitors
ZA202004907B (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
GB2594345B (en) Single dosage shampoo
IL275708A (en) Preferred dosing regimens of G1T38
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
PT3738800T (pt) Equipamento para distribuição de cola com múltiplos componentes sobre uma mistura granular, bem como procedimento para distribuição e utilização do equipamento
IL278889A (en) Dosing regimen for the treatment of PI3K-related disorders
LT3672631T (lt) Farmacinės kompozicijos, kurių sudėtyje yra antikūnų prieš beta amiloidą
HUE066166T2 (hu) ANTI-BCMA hatóanyagok adagolási rendje
IL281958A (en) Pharmaceutical preparations containing bispecific anti-CD37 antibodies
IL291432A (en) Dosage for anti-tryptase antibodies
IL289575A (en) nmda receptor modulators
IL281398A (en) A process for preparing a pharmaceutical coated solid dosage form
HK40071349A (en) Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
GB201914040D0 (en) Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GB202000318D0 (en) Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB201906807D0 (en) Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
PL3972905T3 (pl) Urządzenie dozujące do podawania produktu infuzyjnego
GB2589119B (en) Dosage dispensing system
PL3934814T3 (pl) Dozownik do podawania płynnych produktów
IL267359B (en) Medicine dispenser
HK40049719A (en) Dosing regimen for the treatment of pi3k related disorders
HK40074182A (en) Dosing regimen for anti-dll3 agents
GB201800873D0 (en) Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues